Recruiting studies: Mild Moderate Cognitive Impairment

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET
Phase 3 · 126 location(s) · Bristol-Myers Squibb · NCT06976203 A Phase 2 Study to Assess the Safety of EI-1071 and the Effects of EI-1071 on Neuroinflammation in Alzheimer's Disease P
Phase 2 · 2 location(s) · Elixiron Immunotherapeutics Inc. · NCT06745583 Contributions of mTBI to Neurodegeneration Due to Chronic Traumatic Encephalopathy (CTE) and Alzheimer's Disease (AD)
Phase N/A · 1 location(s) · VA Office of Research and Development · NCT04124029 Train Your Brain Fitness SC: An Exercise Intervention for People With Cognitive Impairments
NA · 2 location(s) · University of South Carolina · NCT06799429 A Study of NTRX-07 in Participants With Alzheimer's Disease
Phase 2 · 6 location(s) · NeuroTherapia, Inc. · NCT07058688 Depressive Symptoms, Cognitive Impairment, and Outcomes in Hospitalized Chronic Heart Failure Patients
Phase N/A · 1 location(s) · Lithuanian University of Health Sciences · NCT07284446 A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
Phase 3 · 116 location(s) · Bristol-Myers Squibb · NCT06976216 Impact of NANO-PSO on Cognition in Older Adults with Mild to Moderate Cognitive Impairment
Phase 2 · 1 location(s) · Distribuidora Biolife SA de CV · NCT06520878 Daridorexant to Treat Insomnia in Patients With Mild Cognitive Impairment and Mild to Moderate Alzheimer Disease
Phase 4 · 1 location(s) · University Hospital, Montpellier · NCT05924425 Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PE
Phase N/A · 26 location(s) · GAP Innovations, PBC · NCT06584357 Repurposing Nucleoside Reverse Transcriptase Inhibitors for Treatment of AD
Phase 1 · 2 location(s) · Butler Hospital · NCT04500847 A Study of Zunveyl on Safety, Tolerability, Neuropsychiatric Symptoms, and Caregiver Distress in Alzheimer's Disease (RE
Phase 4 · 5 location(s) · Alpha Cognition, Inc · NCT07633470

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.